irvin @irvin
18 November, 04:43
#South Africa
#South Africa #South Africa #South Africa #South Africa #South Africa #South Africa #South Africa
youwei wei @youwei
07 September, 06:38
Fancialcms Introduction
Fancialcms is a product distribution center online. All the products are made and shipped from China. The manufacturers are top in area supplying to Walmart/Costco/Target/IKEA such supermarkets and the cost is cheapest compared to other channels

Pay USD150 (service fee) you will get below benefits:

1.Domain, Website and server maintenance support for 1 year (7*24 experts standby face to face).
2.You get 50% B2C order commission from your website
3.You get commission from OEM/ODM or wholesale B2B business. We will support on cost reduction and logistics.
4.Money back guarantee 30 Days if you don’t like the service

As long as you have channels to promote and sell products online or offline, fancialcms will be the fastest way to be CEO. Now below areas is open for joining:
Japan, South Korea, Germany, Australia, New Zealand, Canada, Germany, France, United Kingdom

Contact us to know more:
Email: infofancial.com
Phone/whatsapp: +852 6238 5615
Neetu4u @Neetu4u
23 May, 12:42
2022 - What is the best website for Satta King lottery predictions?

Detailed Reports on Satta King Online Game 2022 is one of the upcoming South Indian games, which is scheduled to be launched later this year or early next year.

For Satta King: https://sattaking01.in/
andobando @andobando
12 April, 10:37
🇿🇦 South Africa Premier
90 Baroka FC - Orlando Pirates => Orlando Pirates @2.22
Michael Doe @go_620609f9cd878
24 February, 07:48
The globe claim to provide contract fill / finish services for various types of biopharmaceutical drug / therapy products.

Despite the fact that biopharmaceuticals offer significant profit margins, innovator companies are plagued by high costs of development, complex production protocols and special procedures and equipment for fill / finish operations. Consequently, a number of drug manufacturers have demonstrated a preference for outsourcing fill / finish operations of such products.

To order this 480+ page report, which features 350+ figures and 260+ tables, please visit this - https://www.rootsanalysis....

The USD 4.2 billion (by 2030) financial opportunity within the biologics fill / finish services market has been analyzed across the following segments:
 Types of Primary Packaging Containers
 Ampoules
 Cartridges
 Syringes
 Vials

 Types of Biologics
 Peptides / proteins
 Antibodies
 Vaccines
 Cell therapies
 Gene therapies
 Viral products
 Oligonucleotides
 Others

 Company Size
 Small-sized
 Mid-sized
 Large / very large

 Scale of Operation
 Preclinical
 Clinical
 Commercial

 Key Therapeutic Areas
 Cancer
 Infectious diseases
 Autoimmune diseases
 Cardiovascular diseases
 Other indications

 Key Geographical Regions
 North America (US, Canada)
 Europe (UK, France, Germany, Italy, Spain and rest of the Europe)
 Asia-Pacific (Japan, China, South Korea, India and Australia)

The Biologics Fill / Finish Services Market, 2019-2030.”report features the following companies, which we identified to be key players in this domain:
 Advanced BioScience Laboratories (ABL)
 Albany Molecular Research (AMRI)
 Biocon
 BioPharma Solutions
 BioReliance
 Boehringer Ingelheim BioXcellence
 ChemPartner
 Emergent BioSolutions
 IDT Biologika
 Lonza
 LuinaBio
 Mycenax Biotech
 Patheon
 Recipharm
 Vetter Pharma
 WuXi Biologics

Table of Contents

1. Preface

2. Executive Summary

3. Introduction

4. Competitive Landscape

5. Company Competitiveness Analysis

6. Biologics Fill / Finish Service Providers in North America: Company Profiles

7. Biologics Fill / Finish Service Providers in Europe: Company Profiles

8. Biologics Fill / Finish Service Providers in Asia-Pacific: Company Profiles

9. Partnerships and Collaborations

10. Recent Expansions

11. Capacity Analysis

12. Demand Analysis

13. Biologics Manufacturing and Fill / Finish: Key Performance Indicator Analysis

14. Market Sizing and Opportunity Analysis

15. Future Growth Opportunities

16. Case Study: Robotic Systems in Fill / Finish Operations

17. Case Study: Ready-to-Use Packaging Components in Aseptic Fill / Finish Operations

18. Conclusion

19. Interview Transcripts

20. Appendix 1: Tabulated Data

21. Appendix 2: List of Companies and Organizations

To purchase a copy, please visit https://www.rootsanalysis....

About Roots Analysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at inforootsanalysis.com

Contact Details
Ben Johnson
+1 (415) 800 3415
ben.johnsonrootsanalysis.com

Roots Analysis
Web: https://www.rootsanalysis....
LinkedIn: https://in.linkedin.com/co...
Twitter: https://twitter.com/RootsA...
Medium: https://medium.com/RootsA...
Pinterest: https://in.pinterest.com/R...
Quora: https://rootsanalysisinsig...
Steffan Joe @go_62036dc494e07
22 February, 07:31
The cell therapy manufacturing market is growing at an annualized rate of 18%, claims Roots Analysis

Given the consistent increase in number of cell therapies being developed and launched, this upcoming therapeutic segment is on its way to becoming one of the highest valued markets within the biopharmaceutical industry

London

Roots Analysis has announced the addition of “Cell Therapy Manufacturing Market (4th Edition), 2021-2030” report to its list of offerings.

Owing to the complex manufacturing processes, requirement of advanced production facilities and the growing demand for cell therapy products, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities.

To order this 620 page report, which features 210+ figures and 280+ tables, please visit https://www.rootsanalysis....

Key Market Insights

Around 200 organizations claim to be engaged in cell therapy manufacturing
The market landscape is dominated by industry players, which constitute 65% of the total number of stakeholders. Amongst these, over 25% companies are large firms.

280+ production facilities dedicated to cell therapies have been established worldwide
North America has emerged as the manufacturing hub for cell therapies, with the presence of nearly 45% of the manufacturing facilities; this is followed by Europe (31%). Other emerging regions include China, Japan, South Korea and Australia.

90 cell therapy manufacturers are focused on immune cell and stem cell therapies
Most of the players in this domain are focused on manufacturing of T cell therapies, primarily CAR-T therapies, while the stem cell therapy manufacturers are primarily engaged in the production of adult stem cells and mesenchymal stem cell therapies

Presently, more than 70 companies carry out manufacturing at all scales of operation.
Nearly 45% players have the required capabilities for commercial scale manufacturing. It is worth noting that all the industry players manufacture cell therapies required for clinical purposes.

35+ companies offer automated and closed systems to cell therapy developers
More than 60 automated and closed systems are being used for cell therapy manufacturing. Organizations that are presently offering customized automated solutions for cell therapy processes / manufacturing are Fraunhofer Institute for Manufacturing Engineering and Automation IPA (Germany), KMC Systems (US), RoosterBio (US) and Mayo Clinic Center for Regenerative Medicine (US).

Several partnerships were established in this domain, during the period 2016-2021
More than 180 deals have been inked during the given time period. A large proportion (34%) of the partnerships were related to manufacturing of cell therapies, followed by acquisitions (17%) and licensing agreements (14%).

Expansion activity in this domain has grown at a CAGR of 59%, between 2016 and 2021
More than 75 facility expansions were reported during the given time period. Over 80% instances were related to the establishment of new facilities, followed by those involving the expansion of existing facilities (17%).

Role of big pharma players in this industry has evolved over the last few years; their initiatives increased at a CAGR of 41% during the period 2016-2020
Several big pharma players have undertaken various initiatives focused on cell therapy manufacturing. Gilead sciences, Takeda Pharmaceutical and Novartis are some of the prominent big pharma players in this domain.

The currently available global cell therapy manufacturing capacity is estimated to be over 1.88 billion sq. ft. of dedicated cleanroom area
The maximum (48%) installed capacity (in terms of cleanroom area) belongs to companies based in North America (48%); the region has higher number of players having multiple production facilities. This is followed by Asia Pacific (29%) and Europe (23%).

The demand for cell therapies is anticipated to grow at a CAGR of 22%, during 2021-2030
Presently, the clinical demand for stem cell and CAR-T cell-based products is the highest; this trend is unlikely to change in the foreseen future as well. On the other hand, the demand for tumor cell, NK cell and dendritic cell therapies is expected to grow at a relatively faster pace, over the next decade.

By 2030, the market for commercial scale cell therapy manufacturing is likely to grow at an annualized rate of 31.5%
Currently, North America and Europe capture more than 70% share of the overall market. Specifically, the cell therapy manufacturing market in Asia Pacific is driven by countries, such as China, Japan, South Korea, India and Singapore. It is worth noting that the current market in Asia Pacific is primarily driven by the clinical demand for cell therapies.

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis....

The USD 14.5 billion (by 2030) financial opportunity associated with cell therapy manufacturing market has been analyzed across the following segments:
 Type of Cell Therapy
 T cell therapies
 Dendritic and tumor cell therapies
 NK cell therapies
 Stem cell therapies
 Other ATMPs

 Source of Cell
 Autologous
 Allogeneic

 Scale of Operation
 Clinical
 Commercial

 Purpose of Manufacturing
 In-house Manufacturing
 Contract Manufacturing

 Geographical Regions
 North America
 Europe
 Asia Pacific
 Rest of the World

The report also features inputs from eminent industry stakeholders, according to whom, the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
 Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
 Gille
Steffan Joe @go_62036dc494e07
09 February, 10:34
Biologics market is projected to be worth USD 156 billion by 2030.
Owing to the numerous benefits offered by biologics, this drug class has become an integral part of the overall pharmaceutical industry, having captured a significant market share over the past couple of decades

Roots Analysis has announced the addition of the “Top Selling Biologics Market, 2021 – 2030” report to its list of offerings.

Over the years, around 200 biologics have been approved for the treatment of various disease indications in the US and Europe. In 2020, 18 new biologics received approval by the USFDA. Despite their complex and cost intensive manufacturing protocols, biopharmaceuticals (once approved) are considered to be highly profitable assets. In the recent past, many biological interventions have achieved blockbuster status (in some cases, registering revenues worth over USD 4 billion a year); prominent examples include (arranged in decreasing order of 2020 revenues) Humira®, Keytruda®, Stelara®, Opdivo®, Avastin®, Trulicity®, Enbrel®, Ocrevus™ and Rituxan®.

To order this 320+ page report, which features 190+ figures and 195+ tables, please visit this https://www.rootsanalysis....
Key Market Insights
More than 65 top selling biologics (revenues equal to or above USD 500 million in 2020) are currently available in the market
Majority (54%) of the aforementioned candidates are monoclonal antibodies, followed by hormones (19%) and enzymes (9%). Further, subcutaneous route (50%) emerged as the most preferred route of administration for such therapies, followed by the intravenous route (40%).

More than 50% the developers of top selling biologics are based in North America
The top selling biologics market is currently dominated by the presence of large companies (82%). Additionally, majority of such players were established before the year 2000.

Over 2,450 clinical trials registered for the evaluation of top selling biologics, till Q3 2020
Of the total, 1,892 trials were registered for the evaluation of products targeting oncological disorders, followed by those investigating biologics intended for the treatment of metabolic disorders (122) and autoimmune disorders (98).

Around 250 biosimilars of top selling biologics are currently approved / under development
Close to 30% of the aforementioned candidates have already been approved. It is worth mentioning that over 100 biosimilars have received approval in Asia Pacific. Within this region, India and South Korea emerged as key hubs, having granted maximum approvals for biosimilars of top selling biologics (in terms of 2020 revenues).

Monoclonal antibodies are anticipated to capture over 75% of the market share by 2030
Over 40% of the market share is anticipated to be capture by Genentech / Roche and Merck by 2030. It is worth mentioning that as the patents of the currently marketed products have already / are expected to expire towards the end of the forecast period, the market is likely to reach maturity.

To request a sample copy / brochure of this report, please visit this
https://www.rootsanalysis....
Key Questions Answered
 Which biologics are likely to attain the blockbuster status in the foreseen future?
 Who are the leading players engaged in the development of top selling biologics?
 Which key clinical conditions are presently targeted by top selling biologics?
 What are the historical global sales of top selling biologics?
 Which are the most commonly adopted product life cycle management strategies by players for their top selling products?
 What is the current annual treatment cost associated with top selling biologics?
 Which regions have emerged as the key hubs for conducting clinical studies focused on top selling biologics?
 How has the biosimilars landscape in this market evolved over the past few years?
 Which factors are likely to influence the evolution of this market?
 How is the current and future market opportunity likely to be distributed across key market segments?

The USD 156 billion (by 2030) financial opportunity associated with the top selling biologics market has been analyzed across the following segments:
Type of Biologic
 Monoclonal Antibodies
 Hormones
 Fusion Proteins
 Enzymes
 Interferons
 Antibody Fragments
 Gene Therapies
 Vaccines

Key Developers
 Genentech / Roche
 AbbVie
 Janssen Biotech / Johnson & Johnson
 Amgen
 Eli Lilly
 Bristol Myers Squibb
 Sanofi
 Novo Nordisk
 Regeneron

For additional details, please visit
https://www.rootsanalysis.... or email salesrootsanalysis.com

You may also be interested in the following titles:
1. Novel T-Cell Immunotherapies Market, 2021-2030
2. TIL-based Therapies Market, 2021-2030
3. Non-Hormonal Therapies Market, 2021-2030
4. Gene Therapy Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
5. Global T-Cell Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030

Contact:
Ben Johnson
+1 (415) 800 3415
+44 (122) 391 1091
Ben.johnsonrootsanalysis.com
tammuzFamily0 @tammuzFamily0
02 October, 08:38
Tammuz Family is an international surrogacy, fertility, and egg donation company. We offer a full range of comprehensive and guaranteed surrogacy and IVF programs.
The company was established by Doron Mamet-Meged in 2008. Over the last decade, it has become one of the world’s leading agencies with offices in Sweden, Denmark, Norway, Iceland, Finland, the United States, Brazil, Mexico, Portugal, China, India, South Africa, Australia, and Israel. Tammuz Family specializes in accessible and affordable surrogacy programs in the United States, Ukraine, Georgia, and Colombia for same-sex couples, straight couples, single men, and single women.

Contact Information:
Tammuz Family
3 Rocky Hill Rd, Andover, MA 01810
(646) 859-3669
Roy.youldoustammuz.com
https://www.tammuz.com

Keywords:
Surrogacy in Georgia
Surrogacy Ukraine
Gay couple surrogacy
Surrogacy for hiv positive couples
Low cost surrogacy in USA
Surrogacy for single man
Surrogacy clinics in USA
Cheap surrogacy in USA
Surrogacy for gay couples
VIPortal INC @wangai
24 September, 09:58
Chitranshu kamal @Chitranshu
10 July, 07:10

Nothing found!

Sorry, but we could not find anything in our database for your search query {{search_query}}. Please try again by typing other keywords.